REFERENCES
1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2018;68:394-424.
2. Akinyemiju T, Abera S, Ahmed M, Alam N, Alemayohu MA, et al; Global Burden of Disease Liver Cancer Collaboration. The burden of primary liver cancer and underlying etiologies from 1990 to 2015 at the global, regional, and national level: results from the Global Burden of Disease Study 2015. JAMA Oncol 2017;3:1683-91.
3. Islami F, Goding Sauer A, Miller KD, Siegel RL, Fedewa SA, et al. Proportion and number of cancer cases and deaths attributable to potentially modifiable risk factors in the United States. CA Cancer J Clin 2018;68:31-54.
4. Goossens N, Hoshida Y. Hepatitis C virus-induced hepatocellular carcinoma. Clin Mol Hepatol 2015;21:105-14.
5. Tan A, Yeh SH, Liu CJ, Cheung C, Chen PJ. Viral hepatocarcinogenesis: from infection to cancer. Liver Int 2008;28:175-88.
6. Kamegaya Y, Hiasa Y, Zukerberg L, Fowler N, Blackard JT, et al. Hepatitis C virus acts as a tumor accelerator by blocking apoptosis in a mouse model of hepatocarcinogenesis. Hepatology 2005;41:660-7.
8. Chen CL, Tsukamoto H, Machida K. Oncogenic signaling pathways and origins of tumor-initiating stem –like cells of hepatocellular carcinomas induced by hepatitis C virus, alcohol and/or obesity. Hepatol Int 2014;8:330-8.
9. Zhang Y. Detection of epigenetic aberrations in the development of hepatocellular carcinoma. Cancer Epigenetics 2014;1238:709-31.
10. Yeh MM, Daniel HDJ, Torbenson M. Hepatitis C associated hepatocellular carcinoma in non-cirrhotic livers. Mod Pathol 2010;23:276-83.
11. Koike K. Hepatitis C virus contributes to hepatocarcinogenesis by modulating metabolic and intracellular signaling pathways. J Gastroenterol Hepatol 2007;22:S108-11.
12. Hoshida Y, Fuchs BC, Bardeesy N, Baumert TF, Chung RT. Pathogenesis and prevention of hepatitis C virus-induced hepatocellular carcinoma. J Hepatol 2014;61:S79-90.
13. Axley P, Ahmed Z, Ravi S, Singal AK. Hepatitis C virus and hepatocellular carcinoma: a narrative review. J Clin Transl Hepatol 2018;6:79-84.
14. Singal AG, Lim JK, Kanwal F. AGA clinical practice update on interaction between oral direct-acting antivirals for chronic hepatitis C infection and hepatocellular carcinoma: expert review. Gastroenterology 2019;156:2149-57.
15. Yu ML, Lin SM, Chuang WL, Dai CY, Wang JH, et al. A sustained virological response to interferon or interferon/ribavirin reduces hepatocellular carcinoma and improves survival in chronic hepatitis C: a nationwide, multicenter study in Taiwan. Antivir Ther 2006;11:985-94.
16. Singal AG, Volk ML, Jensen D, Di Bisceglie AM, Schoenfeld PS. A sustained viral response is associated with reduced liver-related morbidity and mortality in patients with hepatitis C virus. Clin Gastroenterol Hepatol 2010;8:280-8,288.e1.
17. Ogawa E, Furusyo N, Kajiwara E, Takahashi K, Nomura H, et al. Efficacy of pegylated interferon alpha-2b and ribavirin treatment on the risk of hepatocellular carcinoma in patients with chronic hepatitis C: a prospective, multicenter study. J Hepatol 2013;58:495-501.
18. Moon C, Jung KS, Kim DY, Baatarkhuu O, Park JY, et al. Lower incidence of hepatocellular carcinoma and cirrhosis in hepatitis C patients with sustained virological response by pegylated interferon and ribavirin. Dig Dis Sci 2015;60:573-81.
19. Morgan RL, Baack B, Smith BD, Yartel A, Pitasi M, et al. Eradication of hepatitis C virus infection and the development of hepatocellular carcinoma: a meta-analysis of observational studies. Ann Inter Med 2013;158:329-37.
20. van der Meer AJ, Veldt BJ, Feld JJ, Wedemeyer H, Dufour JF, et al. Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis. JAMA 2012;308:2584-93.
21. Janjua NZ, Chong M, Kuo M, Woods R, Wong J, et al. Long-term effect of sustained virological response on hepatocellular carcinoma in patients with hepatitis C in Canada. J Hepatol 2017;66:504-13.
22. El-Serag HB, Kanwal F, Richardson P, Kramer J. Risk of hepatocellular carcinoma after sustained virological response in Veterans with hepatitis C virus infection. Hepatology 2016;64:130-7.
23. Chung RT, Baumert TF. Curing chronic hepatitis C-the arc of a medical triumph. N Engl J Med 2014;370:1576-8.
24. McGlynn EA, Adams JL, Kramer J, Sahota AK, Silverberg MJ, et al. Assessing the safety of direct-acting antiviral agents for hepatitis C. JAMA Network Open 2019;2:e194765.
25. American Association for the Study of Liver Diseases and Infectious Diseases Society of America. Recommendations for testing, managing, and treating hepatitis C. Available from: http://www.hcvguidelines.org [Last accessed on 14 Apr 2020].
26. Kohli A, Shaffer A, Sherman A, Kottilil S. Treatment of hepatitis C: a systematic review. JAMA 2014;312:631-40.
27. Wyles DL, Sulkowski MS, Dieterich D. Management of hepatitis C/HIV coinfection in the era of highly effective hepatitis C virus direct-acting antiviral therapy. Clin Infect Dis 2016;63 Suppl 1:S3-11.
28. Kohli A, Alshati A, Georgie F, Manch R, Gish RG. Direct-acting antivirals for the treatment of chronic hepatitis C in patients with chronic kidney disease. Therap Adv Gastroenterol 2016;9:887-97.
29. Falade-Nwulia O, Suarez-Cuervo C, Nelson DR, Fried MW, Segal JB, et al. Oral direct-acting agent therapy for hepatitis C virus infection: a systematic review. Ann Intern Med 2017;166:637-48.
30. Cheung MCM, Walker AJ, Hudson BE, Verma S, McLauchlan J, et al. Outcomes after successful direct-acting antiviral therapy for patients with chronic hepatitis C and decompensated cirrhosis. J Hepatol 2016;65:741-7.
31. Nahon P, Bourcier V, Layese R, Audureau E, Cagnot C, et al. Eradication of hepatitis C virus infection in patients with cirrhosis reduces risk of liver and non-liver complications. Gastroenterology 2017;152:142-6.
32. Su F, Ioannou GN. Hepatocellular carcinoma risk after direct-acting antiviral therapy. Clin Liver Dis (Hoboken) 2019;13:6-12.
33. Kanwal F, Kramer J, Asch SM, Chayanupatkul M, Cao Y, et al. Risk of hepatocellular cancer in HCV patients treated with direct-acting antiviral agents. Gastroenterology 2017;153:996-1005.e1.
34. Ioannou GN, Green PK, Berry K. HCV eradication induced by direct-acting antiviral agents reduces the risk of hepatocellular carcinoma. J Hepatol 2017. Epub ahead of print. doi: 10.1016/j.jhep.2017.08.030
35. Piñero F, Mendizabal M, Ridruejo E, Herz Wolff F, Ameigeiras B, et al. Treatment with direct-acting antivirals for HCV decreases but does not eliminate the risk of hepatocellular carcinoma. Liver Int 2019;39:1033-43.
36. Davis GL, Alter MJ, El-Serag H, Poynard T, Jennings LW. Aging of hepatitis C virus (HCV)-infected persons in the United States: a multiple cohort model of HCV prevalence and disease progression. Gastroenterology 2010;138:513-21.
37. Lazo M, Nwankwo C, Daya NR, Thomas DL, Mehta SH, et al. Confluence of epidemics of hepatitis C, diabetes, obesity, and chronic kidney disease in the United States Population. Clin Gastroenterol Hepatol 2017;15:1957-64.
38. Waziry R, Hajarizadeh B, Grebely J, Amin J, Law M, et al. Hepatocellular carcinoma risk following direct-acting antiviral HCV therapy: a systematic review, meta-analyses, and meta-regression. J Hepatol 2017;67:1204-12.
39. Singer AW, Reddy KR, Telep LE, Osinusi AO, Brainard DM, et al. Direct-acting antiviral treatment for hepatitis C virus infection and risk of incident liver cancer: a retrospective cohort study. Aliment Pharmacol Ther 2018;47:1278-87.
40. Conti F, Buonfiglioli F, Scuteri A, Crespi C, Bolondi L, et al. Early occurrence and recurrence of hepatocellular carcinoma in HCV-related cirrhosis treated with direct-acting antivirals. J Hepatol 2016;65:727-33.
41. Cabibbo G, Celsa C, Cammà C, Craxì A. Should we cure hepatitis C virus in patients with hepatocellular carcinoma while treating cancer? Liver Int 2018;38:2108-16.
42. Kozbial K, Moser S, Schwarzer R, Laferl H, Al-Zoairy R, et al. Unexpected high incidence of hepatocellular carcinoma in cirrhotic patients with sustained virologic response following interferon-free direct-acting antiviral treatment. J Hepatol 2016;65:856-8.
43. Nault JC, Colombo M. Hepatocellular carcinoma and direct acting antiviral treatments: controversy after the revolution. J Hepatol 2016;65:663-5.
44. Mariño Z, Darnell A, Lens S, Sapena V, Díaz A, et al. Time association between HCV therapy and hepatocellular carcinoma emergence in patients with cirrhosis. The relevance of non-characterized nodules. J Hepatol 2019;70:874-84.
45. Nahon P, Layese R, Bourcier V, Cagnot C, Marcellin P, et al. Incidence of hepatocellular carcinoma after direct antiviral therapy for HCV in patients with cirrhosis Included in surveillance programs. Gastroenterology 2018;155:1436-50.
46. Ogawa E, Furusyo N, Nomura H, Dohmen K, Higashi N, et al; Kyushu University Liver Disease Study (KULDS) Group. Short-term risk of hepatocellular carcinoma after hepatitis C virus eradication following direct-acting anti-viral treatment. Aliment Pharmacol Ther 2018;47:104-13.
47. Ioannou GN, Beste LA, Green PK, Singal AG, Tapper EB, et al. Increased risk for hepatocellular carcinoma persists up to 10 years after HCV eradication in patients with baseline cirrhosis or high FIB-4 Scores. Gastroenterology 2019;157:1264-78.
48. Kanwal F, Kramer JR, Asch SM, Cao Y, Li L, et al. Long-term risk of hepatocellular carcinoma in HCV patients treated with direct acting antiviral agents. Hepatology 2020;71:44-55.
49. Llovet JM, Villanueva A. Liver cancer: effect of HCV clearance with direct-acting antiviral agents on HCC. Nat Rev Gastroenterol Hepatol 2016;13:561-2.
50. Reig M, Boix L, Mariño Z, Torres F, Forns X, et al. Liver cancer emergence associated with antiviral treatment: an immune surveillance failure? Semin Liver Dis 2017;37:109-18.
51. Debes JD, van Tilborg M, Groothuismink ZMA, Hansen BE, Schulze Zur Wiesch J, et al. Levels of cytokines in serum associate with development of hepatocellular carcinoma in patients with HCV infection treated with direct-acting antivirals. Gastroenterology 2018;154:515-7.e3.
52. Sanduzzi-Zamparelli M, Boix L, Leal C, Reig M. Hepatocellular carcinoma recurrence in HCV patients treated with direct antiviral agents. Viruses 2019;11:406.
53. Villani R, Vendemiale G, Serviddio G. Molecular Mechanisms Involved in HCC Recurrence after direct-acting antiviral therapy. Int J Mol Sci 2019;20:49.
54. Singal AK, Freeman DH, Anand BS. Meta-analysis: interferon improves outcomes following ablation or resection of hepatocellular carcinoma. Aliment Pharmacol Ther 2010;32:851-8.
55. Nishibatake Kinoshita M, Minami T, Tateishi R, Wake T, Nakagomi R, et al. Impact of direct-acting antivirals on early recurrence of HCV-related HCC: comparison with interferon-based therapy. J Hepatol 2019;70:78-86.
56. Colombo M, Boccaccio V. HCV therapy and risk of liver cancer recurrence: who to treat? Nat Rev Gastroenterol Hepatol 2018;15:392-3.
57. Reig M, Boix L, Bruix J. The impact of direct antiviral agents on the development and recurrence of hepatocellular carcinoma. Liver Int 2017;37:136-9.
58. Guarino M, Viganò L, Ponziani FR, Giannini EG, Lai Q, et al. Recurrence of hepatocellular carcinoma after direct acting antiviral treatment for hepatitis C virus infection: literature review and risk analysis. Dig Liver Dis 2018;50:1105-14.
59. Guarino M, Sessa A, Cossiga V, Morando F, Caporaso N, et al. Direct-acting antivirals and hepatocellular carcinoma in chronic hepatitis C: a few lights and many shadows. World J Gastroenterol 2018;24:2582-95.
60. Saraiya N, Yopp AC, Rich NE, Odewole M, Parikh ND, et al. Systematic review with meta-analysis: recurrence of hepatocellular carcinoma following direct-acting antiviral therapy. Aliment Pharmacol Ther 2018;48:127-37.
61. Singal AG, Rich NE, Mehta N, Branch A, Pillai A, et al. Direct-acting antiviral therapy not associated with recurrence of hepatocellular carcinoma in a multicenter North American cohort study. Gastroenterology 2019;156:1683-92.
62. Dang H, Yeo YH, Yasuda S, Huang CF, Iio E, et al. Cure with interferon free DAA is associated with increased survival in patients with HCV related HCC from both East and West. Hepatology 2019. Epub ahead of print [PMID: 31610027 DOI: 10.1002/hep.30988]
63. Saberi B, Dadabhai AS, Durand CM, Philosophe B, Cameron AM, et al. Challenges in treatment of hepatitis C among patients with hepatocellular carcinoma. Hepatology 2017;66:661-3.
64. Beste LA, Green PK, Berry K, Kogut MJ, Allison SK, et al. Effectiveness of hepatitis C antiviral treatment in a USA cohort of veteran patients with hepatocellular carcinoma. J Hepatol 2017;67:32-9.
65. Prenner SB, VanWagner LB, Flamm SL, Salem R, Lewandowski RJ, et al. Hepatocellular carcinoma decreases the chance of successful hepatitis C virus therapy with direct-acting antivirals. J Hepatol 2017;66:1173-81.
66. Chang CY, Nguyen P, Le A, Zhao C, Ahmed A, et al. Real-world experience with interferon -free, direct-acting antiial therapies in Asian Americans with chronic hepatitis C and advanced liver disease. Medicine (Baltimore) 2017;96:e6128.
67. Soria A, Fabbiani M, Lapadula G, Gori A. Unexpected viral relapses in hepatitis C virus-infected patients diagnosed with hepatocellular carcinoma during treatment with direct-acting antivirals. Hepatology 2017;66:992-4.
68. Ji F, Yeo YH, Wei MT, Wei B, Dang S, et al. Hepatocellular carcinoma decreases the effectiveness of hepatitis C antiviral treatment: do direct-acting antiviral regimens matter? Hepatology 2018;67:1180-2.
69. Harrod E, Moctezuma-Velazquez C, Gurakar A, Ala A, Dieterich D, et al. Management of concomitant hepatocellular carcinoma and chronic hepatitis C: a review. Hepatoma Res 2019;5:28.
70. Ahmed A, Gonzalez SA, Cholankeril G, Perumpail RB, McGinnis J, et al. Treatment of patients waitlisted for liver transplant with all-oral direct-acting antivirals is a cost-effective treatment strategy in the United Status. Hepatology 2017;66:46-56.
71. Radhakrishnan K, Di Bisceglie AM, Reddy KR, Lim JK, Levitsky J, et al. Treatment status of hepatocellular carcinoma does not influence rates of sustained virologic response: an HCV-TARGET analysis. Hepatol Commun 2019;3:1388-99.
72. Roche B, Coilly A, Duclos-Vallee JC, Samuel D. The impact of treatment of hepatitis C with DAAs on the occurrence of HCC. Liver Int 2018;38:139-45.
73. Belli LS, Berenguer M, Cortesi PA, Strazzabosco M, Rockenschaub SR, et al; European liver and intestine association (ELITA). Delisting of liver transplant candidates with chronic hepatitis C after viral eradication: a European study. J Hepatol 2016;65:524-31.
74. Gadiparthi C, Cholankeril G, Perumpail BJ, Yoo ER, Satapathy SK, et al. Use of direct-acting antiviral agents in hepatitis C virus- infected liver transplant candidates. World J Gastroenterol 2018;24:315-22.
75. Pascasio JM, Vinaixa C, Ferrer MT, Colmenero J, Rubin A, et al. Clinical outcomes of patients undergoing antiviral therapy while awaiting liver transplantation. J Hepatol 2017;67:1168-76.
76. Yang JD, Aqel BA, Pungpapong S, Gores GJ, Roberts LR, et al. Direct acting antiviral therapy and tumor recurrence after liver transplantation for hepatitis C-associated hepatocellular carcinoma. J Hepatol 2016;65:856-68.
